Amgen To Position Neulasta As Prophylaxis For Febrile Neutropenia
Executive Summary
Amgen plans to position the Neupogen follow-on product Neulasta as prophylaxis for infection related to chemotherapy-induced neutropenia
You may also be interested in...
Amgen Projects Neulasta Sales Driven By Prescribing Growth, Not Switches
Amgen expects Neulasta (pegfilgrastim) 2004 sales to be driven by an increase in the patient population and changes in prescribing patterns
Amgen Projects Neulasta Sales Driven By Prescribing Growth, Not Switches
Amgen expects Neulasta (pegfilgrastim) 2004 sales to be driven by an increase in the patient population and changes in prescribing patterns
Inhale To Initiate 10 Proprietary Programs In Two Years, Keep Partner Model
Inhale Therapeutics expects to begin 10 proprietary research programs in the next two years